Examkin

Question

Difficulty: MediumGastroenterology and Hepatology

Match each clinical presentation of a gastrointestinal or hepatobiliary disorder to its most appropriate evidence-based next step in management.

  • A 58-year-old female with known decompensated cirrhosis is evaluated for new-onset lethargy and generalized abdominal discomfort; paracentesis yields fluid with a neutrophil count of 620/mm³.Admit for administration of intravenous third-generation cephalosporins and weight-based albumin infusion.
  • A 65-year-old male is evaluated in the outpatient setting for mild left lower quadrant tenderness; a recent computed tomography scan confirms acute diverticulitis with no evidence of complications, and his vital signs remain normal.Manage conservatively with a short-term clear liquid diet and strict avoidance of routine antimicrobial therapy.
  • A 71-year-old female with a long-standing history of systemic sclerosis reports months of loose stools and unintentional weight loss; laboratory evaluation reveals macrocytic anemia and a positive carbohydrate breath test.Commence a targeted therapeutic course with an oral, non-absorbable antibiotic agent such as rifaximin.
  • A 44-year-old male develops profuse, foul-smelling diarrhea and a white blood cell count of 16,000/µL one week into a course of parenteral ceftriaxone for lobar pneumonia; stool testing is positive.Halt the current antibacterial therapy if clinically feasible and initiate oral fidaxomicin.

Answer

The cirrhotic patient with SBP requires IV cephalosporins and albumin. The patient with uncomplicated diverticulitis should receive conservative management without routine antibiotics. The scleroderma patient with SIBO requires oral rifaximin. The patient with C. difficile colitis should be treated with oral fidaxomicin.
Each clinical presentation is matched to its guideline-directed therapy: SBP requires IV antibiotics and albumin to lower mortality; uncomplicated diverticulitis is managed conservatively without antibiotics to promote stewardship; SIBO requires targeted intraluminal eradication with rifaximin; and severe C. difficile requires oral fidaxomicin.

Step-by-Step Solution

1
Evaluate the clinical vignette of the 58-year-old female with cirrhosis and an ascitic fluid neutrophil count >250/mm³.
Diagnose Spontaneous Bacterial Peritonitis (SBP).
An ascitic neutrophil count of 250/mm³ or greater is the diagnostic threshold for SBP, necessitating immediate treatment to prevent severe complications.
2
Determine the optimal therapy for SBP.
Match with intravenous third-generation cephalosporins and albumin.
IV antibiotics cover typical enteric pathogens, while IV albumin significantly reduces the incidence of renal impairment (hepatorenal syndrome) and improves mortality.
3
Evaluate the 65-year-old male with CT-confirmed acute, uncomplicated diverticulitis and normal vital signs.
Determine that he is a candidate for conservative outpatient management.
He is hemodynamically stable, immunocompetent, and lacks systemic signs of severe infection or CT evidence of complications.
4
Select the appropriate management approach for mild diverticulitis.
Match with conservative management and strict avoidance of routine antimicrobial therapy.
Evidence-based guidelines emphasize antibiotic stewardship, showing no benefit to routine antibiotics in uncomplicated diverticulitis.
5
Evaluate the 71-year-old female with systemic sclerosis, macrocytic anemia, and a positive carbohydrate breath test.
Diagnose Small Intestinal Bacterial Overgrowth (SIBO).
Dysmotility from systemic sclerosis allows colonic bacteria to proliferate in the small bowel, causing malabsorption and a positive breath test.
6
Determine the targeted treatment for SIBO.
Match with oral rifaximin.
Rifaximin is a non-absorbable antibiotic that targets intraluminal bacteria in the gut without causing significant systemic effects.
7
Evaluate the 44-year-old male with profuse diarrhea and leukocytosis following ceftriaxone therapy.
Identify severe Clostridioides difficile infection.
Recent antibiotic use followed by significant diarrhea and an elevated WBC count >15,000/µL are hallmarks of a severe C. difficile infection.
8
Select the first-line management for severe C. difficile.
Match with halting the current antibiotic and initiating oral fidaxomicin.
Fidaxomicin is a preferred first-line agent due to its narrow spectrum and lower recurrence rates compared to oral vancomycin.

Key Concept

Appropriate selection of antimicrobial therapies and implementation of antibiotic stewardship principles in gastrointestinal and hepatobiliary disorders.
Rate this question

Topics

Gastroenterology and Hepatology

More questions from this topic